Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 18 Jan 2017

Evotec launches New Biotech to tackle the Most Deadly Diseases

Evotec has backed the foundation of Fibrocor, a Canadian company that will work on fibrosis, the underlying cause of some of the most deadly diseases. Fibrocor was launched yesterday in Toronto with €2M (CDN 2.8M) from the successful German biotech CRO Evotec and the Canadian non-profit MaRS Innovation. Evotec will provide all drug discovery activities […]

January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Jan 2017

New Combo Therapy for Type 2 Diabetes to Sweep Europe

Zealand Pharma and its partner Sanofi have made it to the European market with a new combination therapy to treat type 2 diabetes. Suliqua, a treatment for type 2 diabetes, has received marketing authorization in Europe. This feat has earned Zealand Pharma a €9.4M ($10M) payment from its partner Sanofi. The big pharma is responsible […]

January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 17 Jan 2017

Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs

Nanoparticles produced by burning fossil fuels could promote viral infections by activating latent viruses in our lungs; what are the consequences? We all know that breathing the traffic smoke is not good for our health. Now, researchers from the Helmholtz Zentrum in Munich have discovered a process that makes it even more dangerous than initially […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Jan 2017

This Herpes Cure is Proving to Work Better than its Predecessors

AiCuris’ candidate pritelivir has shown to perform better than current standard antiviral treatments against genital herpes in Phase II trials. AiCuris, leading the development of treatments for infectious disease, has completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Jan 2017

This Leading Gas Distributor from France is Going Bio

Global Bioenergies and Butagaz will collaborate to develop and incorporate renewable energy sources into France’s energy systems. Butagaz, a gas distributor from France, is partnering with Global Bioenergies, a synbio company in Paris that produces biofuel with renewable sources. Butagaz will support Global Bioenergies’ industrial development in exchange for the first batches of bio-isobutene the […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

German Antibody for Cancer Diagnostics catches an Australian Eye

Wilex is selling Telix Pharmaceuticals its radiolabeled antibody for cancer applications, Redectane, to focus on the development of ADCs instead. The Australian Telix Pharmaceuticals has closed a license agreement with Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

Merck partners with Big Data Unicorn to help Cancer Patients

Merck will use Palantir’s big data software to improve drug development and patient services, starting with cancer treatments. Merck will step up its data analytics capabilities in partnership with Palantir. The US company, co-founded by PayPal billionaire Peter Thiel, provides data integration and analysis software that Merck plans to use to improve patient care and […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

The UK Steps Up its Game in Automated CRISPR Gene Editing

Horizon Discovery now has full access to CRISPR technology and will develop an automated gene editing platform in collaboration with Solentim. Horizon Discovery, based in Cambridge, UK, uses gene editing technology to create custom cell lines for research. To step up its game, the company has upgraded its existing license with ERS Genomics‘ to obtain […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 14 Jan 2017

This Bioartist is Exhibiting Living Portraits of her own Daughters

Gina Czarnecki raises questions about identity and ownership of our own bodies through living artwork that once used to form part of other human beings. Gina Czarnecki, based in London, has used her own daughters’ cells to create unique pieces of art. In her project ‘Heirloom‘, recently exhibited at Medical Museion Copenhagen and created in collaboration […]

January 14, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 12 at 6.46.14 PM 1 e1484300509836

Startup Scout 13 Jan 2017

The Good, the Bad and the Cancer-Fighting Macrophage

We decided to stick around England this week and made a short trip from London to visit the young biotech Macrophage Pharma. The company is developing immuno-oncology technology that could turn ‘bad’ tumor-associated macrophages into ‘good’, cancer-fighting cells. City: Berkhamsted, UK (near London) Founded: 2014 Employees: 1-10 Financial data: €10.38M total raised Mission: Macrophage Pharma develops next-generation immunotherapies […]

January 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 13 Jan 2017

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […]

January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

Evotec launches New Biotech to tackle the Most Deadly Diseases

New Combo Therapy for Type 2 Diabetes to Sweep Europe

Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs

This Herpes Cure is Proving to Work Better than its Predecessors

This Leading Gas Distributor from France is Going Bio

German Antibody for Cancer Diagnostics catches an Australian Eye

Merck partners with Big Data Unicorn to help Cancer Patients

The UK Steps Up its Game in Automated CRISPR Gene Editing

This Bioartist is Exhibiting Living Portraits of her own Daughters

The Good, the Bad and the Cancer-Fighting Macrophage

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!